Taltz ixekizumab injection

Taltz is a prescription medication used to treat several autoimmune conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The active ingredient, ixekizumab, is a monoclonal antibody that targets the IL-17A cytokine, which plays a major role in the inflammation associated with these diseases.

The Taltz brand was developed and is owned by Eli Lilly and Company, a major American pharmaceutical corporation founded in Indianapolis in 1876. While the company is headquartered in the United States, its manufacturing processes for biologics like Taltz often involve complex international networks. The drug substance is typically produced in high-tech facilities in the USA and Ireland, with final assembly and packaging occurring in various global locations including Germany and the USA to meet regional market demands.